LEADER 02295nam  2200577 a 450 
001 9910790067903321
005 20200520144314.0
010   $a1-61728-480-7
035   $a(CKB)2670000000090500
035   $a(EBL)3020935
035   $a(SSID)ssj0000470344
035   $a(PQKBManifestationID)11312432
035   $a(PQKBTitleCode)TC0000470344
035   $a(PQKBWorkID)10411156
035   $a(PQKB)11213554
035   $a(MiAaPQ)EBC3020935
035   $a(Au-PeEL)EBL3020935
035   $a(CaPaEBR)ebr10681073
035   $a(OCoLC)923664583
035   $a(EXLCZ)992670000000090500
100   $a20100616d2010      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aInsulin resistance and nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH)$b[electronic resource] /$fMasato Yoneda ... [et al.]
210   $aNew York $cNova Biomedical Books$dc2010
215   $a1 online resource (64 p.)
225 1 $aMetabolic diseases--laboratory and clinical research
225 1 $aNovinka
300   $aDescription based upon print version of record.
311   $a1-61668-927-7 
320   $aIncludes bibliographical references and index.
327   $aNAFLD and insulin resistance (IR) -- Pathophysiology of NASH : insulin resistance, free fatty acids, and cytokines -- Adiponectin and NASH -- TNF-[alpha] and NAFLD/NASH -- Leptin and NAFLD/NASH -- Peroxisome proliferators-activated receptors (PPARs) and NAFLD/NASH -- Iron overload and NAFLD/NASH -- Mitochondrial abnormalities and NAFLD/NASH -- Genetic influences in NAFLD/NASH -- Therapeutic strategy for NASH patients -- Natural history of NAFLD -- Conclusions.
410  0$aMetabolic diseases--laboratory and clinical research series.
410  0$aNovinka (Series)
606   $aFatty liver
606   $aInsulin resistance
615  0$aFatty liver.
615  0$aInsulin resistance.
676   $a616.3/62
700   $aYoneda$b Masato$01486012
701   $aYoneda$b Masato$01486012
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910790067903321
996   $aInsulin resistance and nonalcoholic fatty liver disease (NAFLD)$93705365
997   $aUNINA